Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

被引：80

作者：

Bowen, Deborah A. ^{[1
]}

Call, Timothy G. ^{[1
]}

Jenkins, Greg D. ^{[1
]}

Zent, Clive S. ^{[1
]}

Schwager, Susan M. ^{[1
]}

Van Dyke, Daniel L. ^{[1
]}

Jelinek, Diane F. ^{[1
]}

Kay, Neil E. ^{[1
]}

Shanafelt, Tait D. ^{[1
]}

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

来源：

LEUKEMIA & LYMPHOMA | 2007年 / 48卷 / 12期

关键词：

CLL; treatment; 17P-; rituximab; methylprednisolone;

D O I：

10.1080/10428190701724801

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond to conventional treatments and have a shorter survival. Studies suggest that high-dose methylprednisolone ( HDMP) has activity in such patients and combining HDMP with rituximab may enhance efficacy. We identified 37 patients with CLL treated with the HDMP-rituximab who had follow-up at Mayo Clinic. Nine of 27 (33%) had deletion of 17p13.1 and six of 27 (22%) had deletion of 11q22.3. After a median of one cycle of HDMP-rituximab, 29 (78%) patients had an objective response according to the National Cancer Institute CLL Working Group Criteria including five of nine patients with deletion of 17p13.1. Eight ( 22%) patients had a complete clinical response. Although well tolerated, 11 (29%) patients developed infectious complications before completing one month of therapy. Three-year survival was 41% (95% CI: 26-66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted.

引用

页码：2412 / 2417

页数：6

共 17 条

[11] Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia [J].